New York, New York – (Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period “). ), of the important March 10, 2025 Lead Plaintiff Deadline.
SO AND: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Regeneron class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=33630 or call Phillip Kim, Esq. to. Call us toll-free at 866-767-3653 or email cases@rosenlegal.com for class action information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must go to court no later than March 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified advisors who have a track record of success in leadership roles. Companies issuing notices often do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually litigate securities class actions, but are simply middlemen who refer clients or work with law firms that actually litigate the cases. Be smart when choosing your advisor. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. At that time, Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese company. Rosen Law Firm was Ranked No. 1 by the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the complaint, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Regeneron paid distributors credit card fees on the condition that the distributors would not charge customers of Eylea, one of Regeneron’s flagship products billed, more, to use a credit card; (2) these payments subsidized the prices customers paid when they purchased Eylea with credit cards; (3) Regeneron then offered a price concession that lowered Eylea’s selling price. (4) Because retina practices were sensitive to higher prices when purchasing vascular endothelial growth factor (“anti-VEGF”) drugs with credit cards, Regeneron’s price concessions represented a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly increased reported Eylea sales; (6) By failing to report payment of credit card fees as price concessions, Regeneron overstated the average selling price (“ASP”) reported to federal regulators, thereby violating the False Claims Act. and (7) as a result of the foregoing, Defendants’ positive statements about Regeneron’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details came to light, the lawsuit says investors suffered harm.
To join the Regeneron class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=33630 or call Phillip Kim, Esq. to. Call us toll-free at 866-767-3653 or email cases@rosenlegal.com for class action information.
No class has been certified. Until a course is certified, you will not be represented by legal counsel unless you hire one. You can choose a lawyer of your choice. You can also remain an absent course participant at this point and do nothing. An investor’s ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.
For updates, follow us on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: / /www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
—————–
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238429